More than half of all lung cancer patients present with. New Combinations in the Treatment of Lung Cancer* A Time for Optimism
|
|
- Tobias Tucker
- 8 years ago
- Views:
Transcription
1 New Combinations in the Treatment of Lung Cancer* A Time for Optimism Paul A. Bunn, Jr., MD; and Karen Kelly, MD Strides have been made in the treatment of lung cancer in the last decade that warrant a more optimistic outlook toward the disease. The recent development of several new agents with single-agent activity, including paclitaxel, docetaxel, vinorelbine, gemcitabine, and irinotecan, is important, and those agents offer even greater potential when they are used in combination chemotherapy regimens or in combined-modality programs. The experience to date with therapy results with these agents in the treatment of lung cancer is reviewed and is compared to results documented with the current standard treatments for lung cancer, namely, cisplatin and cisplatin-based combination regimens. Published and ongoing trials are outlined, and directions for future research and the future goals of lung cancer therapy are outlined. The availability of newer chemotherapeutic agents that are active in lung cancer has led to response rates as high as 40% in the treatment of non-small cell lung cancer. These drugs have been shown to be active in combination drug regimens as well as when combined with radiotherapy. Future research will focus on using these agents in two- and three-drug regimens as radiation sensitizers and in combination programs with new drugs and biological agents with apparent activity against this disease. (CHEST 2000; 117:138S 143S) Key words: cisplatin; combination therapy; docetaxel; gemcitabine; irinotecan; lung cancer; paclitaxel; response rates; survival; vinorelbine Abbreviations: NSCLC non-small cell lung cancer; UFT tegafur and uracil More than half of all lung cancer patients present with stage IIIB disease (22%) or stage IV disease (32%). Traditionally, these patients had median survival times of 1 year, and very few survived for 5 years. 1 The vast majority of these patients died as a result of systemic metastases that could not be cured by available chemotherapeutic agents. The previously available treatments, such as alkylating agents and antimetabolites, which were highly effective against some cancers, produced response rates of 15% in non-small cell lung cancer (NSCLC) patients and did not improve survival rates. 2 Consequently, there was great pessimism regarding the role of chemotherapy in advanced NSCLC. More recently, cisplatin (Platinol; Bristol-Myers Squibb *From the University of Colorado Cancer Center, Denver, CO. Correspondence to: Paul A. Bunn, Jr., MD, University of Colorado Cancer Center, Box B-188, 4200 E 9th Ave, Denver, CO 80262; paul.bunn@uchsc.edu Co.; Princeton, NJ)-based chemotherapy has been shown to improve survival rates in patients of all stage groups of NSCLC, 2 to improve quality of life, and to alleviate symptoms in the majority of patients. 3,4 These results were achieved at costs $20,000 per life-year gained. 5 7 However, because survival gains are minimal and toxicity is greater in patients with performance status of 3 or 4, chemotherapy is clearly indicated only for patients with good functional status. Chemotherapy should rarely be considered for select patients with performance status 3 or 4. During the 1990s, five new drugs were shown to produce response and survival rates equivalent or superior to that achieved with cisplatin. 8,9 These agents include paclitaxel (Taxol; Bristol-Myers Squibb Co.), docetaxel (Taxotere; Rhone-Poulenc Rorer; Collegeville, PA), vinorelbine (Navelbine; Glaxo Wellcome Oncology; Research Triangle Park, NY), gemcitabine (Gemzar; Eli Lilly & Co.; Indianapolis, IN), and irinotecan (Camptosar; Pharmacia & Upjohn Co.; Kalamazoo, MI). Each of these drugs has since been studied in combination regimens with cisplatin or carboplatin, yielding responses in 40 to 50% of patients. 8 In randomized trials, some of these combinations (vinorelbine/cisplatin, gemcitabine/cisplatin, and paclitaxel/cisplatin) were superior to cisplatin alone or cisplatin plus etoposide This article will consider the activity of these new agents and new combinations relative to prior results with cisplatin alone. Cisplatin-Based Chemotherapy The first chemotherapeutic agent proven to improve survival among patients with advanced NSCLC was cisplatin. As a single agent, cisplatin produced responses in 20% of patients. 9 Cisplatin in combination with older agents, such as alkylating agents or antimetabolites, produced higher response rates than cisplatin alone, but most randomized trials showed no survival advantage for combination therapy However, a number of randomized trials from the 1980s did prove that cisplatin-based chemotherapy improved survival in all stages of lung cancer compared with best supportive care (stage IIIB/IV disease), radiotherapy alone (inoperable stage III disease), or surgery alone (stage I-IIIA disease; Table 1). 2 In patients with stage IV NSCLC, survival improved by an average of 2 months at the median and by 10% at 1 year (from 10 to 15% to 20 to 25%). In patients with stage III disease, the median survival time was about 4 months longer and the 5-year survival rate improved by 5 to 15%. Cisplatin-based therapies reduced the hazard rate of death in stages I and II NSCLC by 13%, yielding a 5% greater 5-year survival rate. The studies involving early-stage disease included the fewest number of patients, which perhaps is responsible for the borderline significance (p 0.08). 2 The patient self-assessed quality of life associated with cisplatin-based therapy vs best supportive care in stage IV NSCLC or vs radiotherapy in stage III NSCLC also was evaluated in some randomized trials. 3 Cisplatin-based therapy was shown to improve quality of life compared with best supportive care (and radiotherapy where indicated) in both stages III and IV NSCLC. Although only about 25% of patients with stage IV NSCLC and 50 to 138S Multimodality Approach to Lung Cancer
2 Table 1 Meta-Analysis of Randomized Trials With Cisplatin-Based Therapy* Stage Median Survival, mo Long-term Survival, % Cisplatin BSC Cisplatin BSC 60% with stage III disease responded to cisplatin and cisplatin-based combinations, the majority of patients (66% with stage IV and 78% with stage III) experienced relief of lung cancer-related symptoms. 4 When cisplatin or older two-drug cisplatin combinations are administered on an outpatient basis, the cost of care for stage IV patients is less than the costs associated with best supportive care alone. 5 7 In earlier stages of NSCLC, the costs of outpatient cisplatin-based chemotherapy are $20,000 per life-year gained. 5,6 The New Agents Activity in Advanced-Stage NSCLC p Value IV III I, II *From Non-small Cell Lung Cancer Collaborative Group. 2 BSC best supportive care. 1-year survival. Includes chest radiotherapy. 5-year survival. Includes surgery. Experience with the taxanes in the treatment of advanced NSCLC is thoroughly reviewed in this supplement by Dr. Belani. This section, therefore, will focus on results with vinorelbine, gemcitabine, and irinotecan, each of which produces objective responses in 20% of patients with advanced NSCLC (Table 2). 8 In stage IIIB and stage IV NSCLC, each of these agents generates median survival times of about 40 weeks, with about 40% of patients alive at 1 year. These results are superior to those reported for cisplatin or older agents. 9 In addition, when combined with cisplatin, each of these agents produced superior response rates and improved survival times compared to any agent alone. 8 These results are now being confirmed in prospective, randomized clinical trials in patients with advanced NSCLC (Table 3). Combinations of cisplatin or carboplatin with vinorelbine, 10,11 paclitaxel, 12,13,17,18 or gemcitabine 14 have produced higher response rates and longer survival durations than those achieved with cisplatin or vinorelbine alone. Single-agent gemcitabine produced equivalent response rates and survival durations compared with the combination of etoposide and cisplatin. 15,16 The combinations of vinorelbine plus cisplatin, paclitaxel plus carboplatin, and gemcitabine plus cisplatin resulted in 1-year survival rates of 35 to 40%, which is higher than those observed with older, cisplatin-based therapies and confirms that these new agents can prolong survival times in patients with advanced-stage NSCLC. Costs Associated With the Use of New Agents Because new chemotherapeutic agents generally are under patent protection, costs associated with the purchase and administration of these drugs can be high. It is important, therefore, to consider the cost-effectiveness of treating patients with advanced NSCLC, especially in our society, which is very conscious of health-care expenditures. In the original randomized study of chemotherapy vs best supportive care conducted by the National Cancer Institute of Canada, 7 patients receiving best supportive care spent more days in the hospital and received more radiotherapy than patients receiving outpatient chemotherapy. This led to lower overall costs among the outpatient chemotherapy group. However, treating patients with vindesine plus high-dose cisplatin (120 mg/m 2 )as inpatients was more expensive than best supportive care due to the higher hospital and chemotherapy costs. Nonetheless, patients treated with chemotherapy lived longer such that the costs per life-year gained were $20,000. A reexamination of costs in the province of Ontario, Canada, a decade later (1995) again showed that patients receiving outpatient chemotherapy with etoposide and cisplatin had lower costs than patients receiving best supportive care because of fewer hospital days and less use of radiotherapy. 5 The most expensive new agents, the taxanes, vinorelbine, and gemcitabine, increased the immediate costs compared to best supportive care but also extended survival times. Thus, when calculated on the basis of the cost per life-year gained, combinations of cisplatin with paclitaxel, vinorelbine, or gemcitabine cost $20,000 per life-year gained. This $20,000 figure is often used as a threshold of cost-effectiveness in Canada, where the cost of therapies determines their acceptability. 5 Table 2 Phase II Results with Vinorelbine, Gemcitabine, and Irinotecan Alone or in Combination With Cisplatin* Therapy No. of Patients Response, % Median Survival, wk 1-yr Survival Rate, % Vinorelbine Vinorelbine/cisplatin Gemcitabine Gemcitabine/cisplatin Irinotecan NR Irinotecan/cisplatin NR *Reprinted with permission from Bunn and Kelly. 8 NR not reported. CHEST / 117 / 4/ APRIL, 2000 SUPPLEMENT 139S
3 Table 3 Results of Randomized Trials Comparing Combinations of New Agents to Older Cisplatin-Based Therapy* Therapy Reference No. of Patients Response, % Median Survival, wk 1-yr Survival Rate, % Cisplatin Cisplatin/vinorelbine Vinorelbine Vinorelbine/cisplatin Cisplatin Gemcitabine/cisplatin Gemcitabine Cisplatin/etoposide Gemcitabine NR Cisplatin/etoposide NR *See Table 2 for abbreviation. Activity in Patients With Stages I to III NSCLC The greatest benefit of the new agents that are active in NSCLC is likely to be found in early-stage disease. A meta-analysis of cisplatin-based therapies showed that they lowered the hazard rate of death in stages I and II NSCLC by 13%, 2 and the new agents could have even greater benefit. In the United States and Canada, an ongoing intergroup study will determine the benefit of postoperative adjuvant vinorelbine plus cisplatin compared with no further therapy among patients with completely resected stage I or II NSCLC. In another article in this supplement, we review studies of these new combinations that are being used preoperatively and postoperatively as adjuvant therapy. If randomized trials show that preoperative or postoperative administration of one of the new combinations improves survival, it may be possible to identify an adjuvant or neoadjuvant regimen for routine use. Radiosensitization is an important property of many cancer chemotherapeutic agents. A meta-analysis of randomized trials of treatment for stage III NSCLC indicated that the addition of cisplatin-based chemotherapy combinations to radiotherapy results in improved survival compared with radiotherapy alone. 2 Sequential, alternating, and concurrent delivery of chemotherapy and radiotherapy each have produced superior survival rates compared with radiotherapy alone. In a European study, concurrent daily administration of cisplatin plus radiotherapy increased local control and survival. 19 In another randomized trial from Europe, daily carboplatin and etoposide were administered concurrently with twice-daily radiotherapy and were followed by full-dose chemotherapy when the radiotherapy was complete. 20 With 23% of patients alive at 4 years, this regimen was deemed successful. Similarly, the concurrent approach was found superior to a sequential approach for patients with NSCLC in a randomized Japanese trial. 21 Thus, concurrent chemotherapy and radiotherapy are currently believed to provide the best local control and survival rates for patients with stage III NSCLC; the administration of full-dose chemotherapy before or after the concurrent bimodality regimen may reduce distant recurrence and improve survival rates even further. The taxanes have been successfully combined with concurrent radiotherapy. Caution must be observed, however, when combining some of the other new chemotherapeutic agents with radiotherapy due to their potential for radiosensitizing healthy tissues as well as tumors. For instance, the concurrent administration of full-dose gemcitabine and chest radiotherapy resulted in a high rate of esophageal and pulmonary toxicity in early studies. 22 Fulldose irinotecan or gemcitabine plus full-dose chest radiotherapy should remain experimental until definitive studies are published. Future Directions Combination therapy using paclitaxel, vinorelbine, gemcitabine, or irinotecan together with cisplatin or carboplatin has produced results superior to older therapies. However, none of the new two-drug combinations provides a clear benefit, with respect to efficacy or toxicity, over the other. A direct comparison of five of the new combinations is being conducted by the Southwest Oncology Group and the Eastern Cooperative Oncology Group to determine the most effective and least toxic combination. Still, for the future we must attempt to increase the 1-year survival rate beyond 40%. One approach to this goal is to develop two- or threedrug combinations utilizing these new agents. With five new active compounds, in addition to cisplatin and carboplatin, the number of potential combinations is large. Because each of these agents causes myelosuppression, the risk of this dose-limiting toxicity with all of the agents will likely warrant dose reductions when they are given in combination. The combinations of paclitaxel and docetaxel or cisplatin and carboplatin are unlikely to be useful because the mechanisms of action are the same. Phase I studies of new combination regimens are currently underway (Table 4). Preliminary results from some of those studies suggest that full doses of docetaxel, paclitaxel, or vinorelbine can be combined with full doses of gemcitabine. Various schedules being explored in phase II trials include the following: every other week; weekly 2 every 3 weeks; and day 1 paclitaxel or docetaxel with day 1 and 8 gemcitabine every 3 weeks. It also appears that paclitaxel, docetaxel, or vinorelbine can be combined safely with gemcitabine and carboplatin, with all three 140S Multimodality Approach to Lung Cancer
4 Table 4 Examples of New Drug Combinations in Ongoing Phase I/II Studies Drug Combinations Two-drug combinations Paclitaxel gemcitabine Docetaxel gemcitabine Vinorelbine gemcitabine Three-drug combinations Paclitaxel gemcitabine carboplatin Docetaxel gemcitabine carboplatin Vinorelbine gemcitabine carboplatin Paclitaxel gemcitabine vinorelbine drugs given at full doses. It will be important to determine whether such three-drug combinations offer superior results compared with the two-drug combinations. At the University of Colorado Cancer Center, we completed a phase I/II study of the three-drug combination of paclitaxel, gemcitabine, and carboplatin (Table 5). 23 Growth factor support was not used routinely, however, in the event of grade 4 neutropenia lasting for 2 days or febrile neutropenia, granulocyte colony-stimulating factor was administered on subsequent courses. Only 2 of the first 35 patients received granulocyte colony-stimulating factor during any cycle. Grade 4 thrombocytopenia, which never occurred in our phase I and II studies of paclitaxel and carboplatin, occurred with the three-drug regimen in several patients on the first three dose levels after four to six cycles. The carboplatin area under the concentrationvs-time curve dose subsequently was lowered from a target of 6 to 5, and protocol dose reductions were required when nadir platelet counts were below 100,000/ L. Grade 4 thrombocytopenia has not been a problem since these changes were instituted. The major toxicities in this study were myelosuppression and myalgia/arthralgia/neuropathy, which have been sufficiently severe in some patients to require analgesics, anti-inflammatory agents, steroids, or gabapentin. These toxicities have been reversible and did not warrant the Table 5 University of Colorado Phase I/II Study of Paclitaxel, Gemcitabine, and Carboplatin in Advanced NSCLC* Study Level No. of Patients Paclitaxel, mg/m 2 Carboplatin, AUC Gemcitabine, mg/m 2 I II III IV V *Adapted from Bunn. 23 AUC area under the concentration-vstime curve. Paclitaxel given IV over 3honday1;cycles repeated every 21 days. Carboplatin given IV over 30 min on day 1; cycles repeated every 21 days. Gemcitabine given IV over 30 min on days 1 and 8; cycles repeated every 21 days. Table 6 Selected Other New Chemotherapeutic Agents Under Investigation in Lung Cancer UFT Tirapazamine Multitargeted antifolate Oxaliplatin Amifostine Chemotherapeutic Agents removal of patients from the study. In fact, all patients received at least four cycles of therapy, with none exhibiting disease progression during these cycles. The preliminary response and survival data have been encouraging. The next step would be a randomized trial comparing the three-drug regimen to the combinations of paclitaxel and carboplatin or paclitaxel and gemcitabine. Because myelosuppression limits the ability to give full doses of many of these combinations, another strategy is to alternate the administration of the agents or of the two-drug combinations. This strategy has been used in patients with breast cancer, although no results have yet been published. Results of phase II studies using this approach in lung cancer are eagerly awaited. A number of other new agents are being evaluated in patients with lung cancer (Table 6). Although several years ago it appeared unlikely that any antimetabolite would be effective against NSCLC, gemcitabine has proven to be a highly active agent. Two other new antimetabolites are now being studied in NSCLC patients. Eli Lilly & Company is studying a new multitargeted antifolate that has shown preliminary responses in 20% of patients. 24 Bristol-Myers Squibb is studying the oral combination product tegafur and uracil (UFT). In a Japanese study, both UFT alone and UFT in combination with cisplatin were shown to prolong survival when given postoperatively. 25 Tirapazamine (Sanofi Pharmaceutical; New York, NY) is a hypoxic cell sensitizer to drugs (such as cisplatin) and to radiotherapy. Phase II studies have established the safety and efficacy of the two-drug combination of tirapazamine and cisplatin. 26 Phase III studies comparing tirapazamine and cisplatin to cisplatin alone are in progress. Sanofi Pharmaceutical also makes oxaliplatin, a drug that is structurally similar to cisplatin and carboplatin, with a considerably different preclinical spectrum of activity. 27 Many cisplatin-resistant NSCLC cell lines are sensitive to oxaliplatin; clinical trials involving NSCLC patients are in progress. Amifostine is a drug-protective and radiation-protective agent that has been shown to reduce nephrotoxicity, ototoxicity, neurotoxicity, and myelosuppression in patients receiving multiple cycles of high-dose cisplatin and carboplatin. 28 It also has been evaluated among NSCLC patients receiving cisplatin alone, radiation and chemotherapy, paclitaxel plus cisplatin, and paclitaxel plus carboplatin. 28,29 Summary Chemotherapy prolongs survival, relieves symptoms, and improves quality of life (as assessed by the patients CHEST / 117 / 4/ APRIL, 2000 SUPPLEMENT 141S
5 themselves) among patients with NSCLC. The cost per life-year gained that is associated with chemotherapy for NSCLC is similar to or lower than that of other accepted medical therapies. Therefore, we should abandon the prior pessimistic attitude toward the treatment of lung cancer patients and offer them optimal therapy. New chemotherapy combinations are more effective and less toxic than older cisplatin-based combinations and, in addition, can improve their quality of life. These combinations, therefore, should be considered for all lung cancer patients. Future studies will attempt to improve patient outcomes by using the newer agents that are active against NSCLC, with or without cisplatin (or carboplatin), by testing these combinations in earlier stages of disease, and by evaluating these chemotherapy regimens when they are combined with radiotherapy. The results of these trials will determine whether any new combination offers a benefit over others and whether the combination of two or more of the new agents is superior to one of the new agents when it is combined with cisplatin or carboplatin. There are now sufficient phase II study results with concurrent paclitaxel, carboplatin, and radiation therapy to proceed to randomized comparisons against older cisplatin-based concurrent programs. There are phase I and II studies investigating the role of new agents in combined-modality regimens, which, hopefully, will warrant future phase II randomized studies. Perhaps the greatest potential for increasing the cure rate lies with the neoadjuvant and adjuvant use of these new combinations. References 1 Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: meta-analysis using updated data in individual patients from 52 randomized clinical trials. BMJ 1995; 311: Billingham LJ, Cullen MH, Woods J, et al. Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: results of a randomized trial evaluating palliation and quality of life [abstract]. Lung Cancer 1997; 18(suppl 1):9 4 Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. Br J Cancer 1995; 71: Evans WK. Treatment of non-small cell lung cancer with chemotherapy is controversial because of low response and high cost. Lung Cancer 1997; 18(suppl 12): Evans WK, Will BP, Berthelot JM, et al. The cost of managing lung cancer in Canada. Oncology 1995; 9(suppl 11): Jaakinainen L, Goodwin PJ, Pater L, et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol 1990; 8: Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998; 5: Bunn PA Jr. The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin Oncol 1989; 16(suppl 6): Wozniak A, Crowley J, Balcerzak S, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16: LeChavalier T, Pujol JL, Douillard JY, et al. A three arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis. Semin Oncol 1994; 21: Bonomi P, Kim K, Kusler J, et al. Cisplatin/etoposide vs paclitaxel/cisplatin/g-csf vs paclitaxel/cisplatin in non-smallcell lung cancer. Oncology 1997; 11(4 suppl 3): Giaccone G, Splinter T, Debruyne C, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer: The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998; 16: Sandler A, Nemunaitis J, Dehnam C, et al. Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1998; 17:454a 15 Perng RP, Chen YM, Liu JM, et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small cell lung cancer in a phase II randomized study. J Clin Oncol 1997; 15: Manegold C, Bergman B, Chemaissani A, et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small cell lung cancer. Ann Oncol 1997; 8: Belani CP, Natale RB, Lee JS, et al. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol Annu Meet 1998; 17:455a 18 Kosmidis P, Mylonakis N, Fountzilas G, et al. Paclitaxel (175 mg/m 2 ) plus carboplatin versus paclitaxel (225 mg/m 2 ) plus carboplatin in non-small cell lung cancer: a randomized study. Semin Oncol 1997; 24(suppl 12):S12-30 S Schaake-Koning C, Van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable nonsmall cell lung cancer. N Engl J Med 1992; 326: Jeremic B, Shibamoto Y, Acimoric L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide stage III non-small cell lung cancer. J Clin Oncol 1996; 14: Furuse K, Fukuoka M, Takada Y, et al. Phase III study of concurrent vs sequential thoracic radiotherapy (TRT) in combination with mitomycin(m), Vindesine(V) and Cisplatin(P) in unresectable stage III non-small cell lung cancer (NSCLC): five-year median follow-up results [abstract]. Proc Am Soc Clin Oncol Annu Meet 1999; 18:458a 22 Vokes E, Gregor A, Turrisi A. Gemcitabine and radiation therapy for non-small cell lung cancer. Semin Oncol 1998; 25(suppl 9): Bunn P Jr. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non small cell lung cancer. Semin Oncol 1999; 26(suppl 4): Postmus P, Green M. Overview of MTA in the treatment of non-small cell lung cancer. Semin Oncol 1999; 26(suppl 4): Tanaka F, Miyahara R, Ohtake Y, et al. Advantage of post-operative oral administration of UFT (tegafur and uracil) 142S Multimodality Approach to Lung Cancer
6 for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 1998; 14: Treat J, Johnson E, Langer C, et al. Tirapazamine with cisplatin in patients with advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1998; 16: Monnet I, Brienza S, Hugret F, et al. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC): ATTIT Association pour le Traitement des Tumeurs Intra Thoraciques. Eur J Cancer 1998; 34: Selvaggi G, Belani CP. Carboplatin and paclitaxel in nonsmall cell lung cancer: the role of amifostine. Semin Oncol 1999; 26(suppl 7): Tannehill S, Mehta M, Larson M, et al. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small cell lung cancer: results of a phase II trial. J Clin Oncol 1997; 15: CHEST / 117 / 4/ APRIL, 2000 SUPPLEMENT 143S
NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationControversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction:
Inoperable NSCLC Controversies in Management of Inoperable NSCLC Introduction: It is difficult to overemphasize the magnitude of lung cancer as Public Health Problem in our society. - In US, Lung cancer
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationSECOND-LINE CHEMOTHERAPY in advanced non
Gemcitabine as Second-Line Treatment for Advanced Non Small-Cell Lung Cancer: A Phase II Trial By Lucio Crinò, Anna Maria Mosconi, Giorgio Scagliotti, Giovanni Selvaggi, Silvia Novello, Massimo Rinaldi,
More informationAdjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer
REVIEW ARTICLE Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer Eckart Laack, Carsten Bokemeyer, Dieter Kurt Hossfeld SUMMARY Introduction: In non-small cell lung cancer (NSCLC)
More informationKey words: chemotherapy; evidence-based medicine; guidelines; non-small cell lung cancer
Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer* Mark A. Socinski, MD, FCCP; David E. Morris, MD; Gregory A. Masters, MD, FCCP; and Rogerio Lilenbaum, MD Stage IV non-small cell lung
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationScottish Medicines Consortium
Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS
More informationStage IIIB disease includes patients with T4 tumors,
Guidelines on Treatment of Stage IIIB Non-small Cell Lung Cancer* James R. Jett, MD, FCCP; Walter J. Scott, MD, FCCP; M. Patricia Rivera MD, FCCP; and William T. Sause, MD, FACR Stage IIIB includes patients
More informationSchedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8
Carboplatin/Gemcitabine Lung Cancer (non-small cell) - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total
More informationReview. The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC)
Annals of Oncology 10 (Suppl. 5): S13-S17,1999. 1999 Kluwer Academic Publishers. Printed in the Netherlands. Review The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC) A. Ardizzoni,
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationREPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group Educational session Treatment of stage III non-small cell lung cancer (NSCLC) in
More informationRecent Trends in Management of Unresectable Non-Small Cell Lung Cancer (NSCLC)
Bahrain Medical Bulletin, Vol.23, No.4, December 2001 Recent Trends in Management of Unresectable Non-Small Cell Lung Cancer (NSCLC) Jalal Al-Maskati, MBChB, ABIM * Lung cancer is a major health problem
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationNon-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationSmall Cell Lung Cancer* State-of-the-Art Therapy 1994
Small Cell Lung Cancer* State-of-the-Art Therapy 1994 Daniel C. Ihde, MD In the United States, small cell lung cancer (SCLC) accounts for about 20% of all cases of lung cancer. Without treatment, tumor
More informationthe standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009
Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy
More informationSystemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions Suresh Ramalingam, a Chandra Belani b a Lung & Thoracic Malignancies Program, University of Pittsburgh
More informationRadiation Therapy in the Treatment of
Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:
More informationCytotoxic Therapy in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions
More informationTable of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
More informationOut-Patient Chemotherapy for Lung Cancer
Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent
More informationSAKK Lung Cancer Group. Current activities and future projects
SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation
More informationChapter 7: Lung Cancer
Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin
More informationTreatment of Advanced Non Small-Cell Lung Cancer: A Review of Current Randomized Clinical Trials and an Examination of Emerging Therapies
Progress in the treatment of advanced non small-cell lung cancer allows patients to live longer and with better quality of life. Milton Rochman. Mother s Comfort. Acrylic on canvas, 24 30. Courtesy of
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More informationSmall-Cell Lung Cancer: Is There a Standard Therapy?
Small-Cell Lung Cancer: Is There a Standard Therapy? Review Article [1] January 02, 1998 By Pieter E. Postmus, MD, PhD [2] and Egbert F. Smit, MD [3] For more than 25 years, chemotherapy has been the cornerstone
More informationSummary ID# 13095. Clinical Study Summary: Study H3E-EW-B012
Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically
More informationTreatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline
Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline An ASCO Endorsement of Treatment of Small Cell Lung Cancer:
More informationShifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer
J Hong Kong Col Radiol. 2010;13(Suppl):S16-21 ORIGINAL ARTICLE Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer VHF Lee Department of Clinical Oncology, Queen Mary Hospital,
More informationChemotherapy for advanced non small-cell lung cancer: role of paclitaxel and gemcitabine
Chemotherapy for advanced non small-cell lung cancer: role of paclitaxel and gemcitabine WK Lam, KWT Tsang, MSM Ip Objective. To review the role of chemotherapy in advanced non small-cell lung cancer,
More informationSur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four
More informationStage I, II Non Small Cell Lung Cancer
Stage I, II Non Small Cell Lung Cancer Best Results T1 (less 3 cm) N0 80% 5 year survival No Role Adjuvant Chemotherapy Radiation Therapy Reduces Local Recurrence No Improvement in Survival 1 Staging Mediastinal
More informationAdiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
More informationCHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago
CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER Walter Stadler, MD University of Chicago Chemotherapy Doctor Terms Drugs used to treat cancer Will attack cancer no matter where it is located
More informationNon small-cell lung cancer, mesothelioma, and thymoma
CHAPTER 7 Non small-cell lung cancer, mesothelioma, and thymoma Robert J. McKenna, Jr., MD, Benjamin Movsas, MD, Dong M. Shin, MD, and Fadlo R. Khuri, MD NSC LUNG In the United States, lung cancer has
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationTaxotere: Clinical Trials in Non-Small Cell Lung Cancer -- Ornstein and Rigas 3 (2): 86...
Page 1 of 11 HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH SEARCH RESULT The Oncologist, Vol. 3, No. 2, 86-93, April 1998 1998 AlphaMed Press This Article Taxotere: Clinical Trials in Non-Small Cell
More informationPostoperative Adjuvant Chemotherapy, with or without Radiotherapy, in Completely Resected Non-Small Cell Lung Cancer
EBS 7-1-2 EDUCATION AND INFORMATION 2013 Evidence-based Series 7-1-2: EDUCATION AND INFORMATION- 2013 Postoperative Adjuvant Chemotherapy, with or without Radiotherapy, in Completely Resected Non-Small
More informationSummary of treatment benefits
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
More informationCetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient
Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)
More informationLUNG CANCER TREATMENT REGIMENS (Part 1 of 7)
LUNG CANCER TREATMENT S (Part 1 of 7) Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration,
More informationSurvey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales
Eur Respir J 1997; 10: 1552 1558 DOI: 10.1183/09031936.97.10071552 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Survey on the treatment
More informationPOLICY A. INDICATIONS
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below
More informationCorso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
More informationThird-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status
Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 209e214 Original Article Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with
More informationNew Trends & Current Research in the Treatment of Lung Cancer, Pt. II
New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationOutcomes of Patients With Stage III Nonsmall Cell Lung Cancer Treated With Chemotherapy and Radiation With and Without Surgery
Outcomes of Patients With Stage III Nonsmall Cell Lung Cancer Treated With Chemotherapy and Radiation With and Without Surgery Hale B. Caglar, MD 1 ; Elizabeth H. Baldini, MD, MPH 1 ; Megan Othus, MS 2
More informationTreatment of Stage III Non-small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Treatment of Stage III Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of
More informationHarmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
More informationINTRODUCTION. liver neoplasms, adrenal gland neoplasms, non small-cell lung cancer, radionuclide imaging, bisphosphonates,
VOLUME 22 NUMBER 2 JANUARY 15 2004 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A L A R T I C L E American Society of Clinical Oncology Treatment of Unresectable Non Small-Cell Lung Cancer Guideline:
More information4.8 Lung cancer. 4.8.5 In the UK, three fractionation regimens are most commonly used:
4.8 Lung cancer 4.8.1 In 2005, both NICE (National Institute for Health and Clinical Excellence) and SIGN (Scottish Intercollegiate Guidelines Network) published guidelines on the management of lung cancer.
More informationItalian clinical research in non-small-cell lung cancer
Annals of Oncology 16 (Supplement 4): iv110 iv115, 2005 doi:10.1093/annonc/mdi919 Italian clinical research in non-small-cell lung cancer C. Gridelli 1, A. Rossi 1, D. Galetta 2, P. Maione 1, C. Ferrara
More informationLung cancer (non-small-cell)
Patient information from the BMJ Group Lung cancer (non-small-cell) It can be devastating to find out that you or someone close to you has lung cancer. You will have to make some important decisions about
More informationPeople Living with Cancer
Patient Guide ASCOInformation for People Living with Cancer ADVANCED LUNG CANCER TREATMENT Recommendations of the American Society of Clinical Oncology Welcome The American Society of Clinical Oncology
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationSpecial Article. Received 5 December 2014; revised 18 February 2015; accepted 25 February 2015. Practical Radiation Oncology (2015) 5, 141-148
Practical Radiation Oncology (2015) 5, 141-148 www.practicalradonc.org Special Article Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationCHAPTER 6: TREATMENT FOR SMALL CELL LUNG CANCER
CHAPTER 6: TREATMENT FOR SMALL CELL LUNG CANCER INTRODUCTION This chapter provides an overview of treatment for small cell lung cancer (SCLC). Treatment options are presented based on the extent of disease.
More informationDOXETAXEL IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER PATIENTS: CLINICAL EFFICACY AND QUALITY OF LIFE
SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH DOXETAXEL IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER PATIENTS: CLINICAL EFFICACY AND QUALITY OF LIFE Thitiya Sirisinha 1, Suwanee Sirilertrakul 2, Manmana
More informationThe expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy
17 (Supplement 10): x108 x112, 2006 doi:10.1093/annonc/mdl247 The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy E. Felip & E. Vilar Oncology Department, Vall d
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
More informationConcurrent Chemotherapy and Radiotherapy for Head and Neck Cancer
Concurrent Chemotherapy and Radiotherapy for Head and Neck Cancer Ryan J. Burri; Nancy Y. Lee Published: 03/23/2009 Abstract and Introduction Abstract Head and neck cancer is best managed in a multidisciplinary
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical
More informationManagement of Stage III, N2 NSCLC: A Virtual Thoracic Oncology Tumor Board
Management of Stage III, N2 NSCLC: A Virtual Thoracic Oncology Tumor Board Abstract Introduction Management of stage III non small-cell lung cancer (NSCLC) is complex and requires careful work-up, staging,
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationMedication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010
Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015
More informationIs an evidence-based approach realistic in non-small cell lung cancer (NSCLC)?
Is an evidence-based approach realistic in non-small cell lung cancer (NSCLC)? Authors Key words P.A. Coucke, N. Barthelemy, L. Bosquee, J.P. van Meerbeeck NSCLC, sequential and concomitant chemo-radiotherapy,
More informationPharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain
Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the
More informationDecision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
More informationPulmonary Complications of Cancer Therapy. Marc B. Feinstein, MD Pulmonary Division Memorial Sloan-Kettering Cancer Center
Pulmonary Complications of Cancer Therapy Marc B. Feinstein, MD Pulmonary Division Memorial Sloan-Kettering Cancer Center Tobacco About 85% of lung cancers occur in current/former smokers. Tobacco causes
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Lung Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Approval Date: April 2007 Revised: November 2008 This guideline is a statement of consensus of the Thoracic Disease Site Team
More informationChemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
More informationHow To Treat A Lung Cancer With Platinum Based Chemotherapy
Original article Annals of Oncology 15: 419 426, 2004 DOI: 10.1093/annonc/mdh087 Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationStage 3 Lung Cancer - Know YourSurviving Conditions
Survival of Stage IIIb and IV Non-Small Cell Lung Cancer Patients on Best Supportive Care in Manitoba, Canada Erich Kliewer Alain Demers Sri Navaratnam Coreen Hildebrand Grace Musto Report for AstraZeneca
More informationAltered Fractionation of Radical Radiation Therapy in the Management of Unresectable Non-Small Cell Lung Cancer
Evidence-based Series #7-12 Version 2 A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Altered Fractionation of Radical Radiation Therapy in the Management of
More informationNON-SMALL CELL LUNG CANCER STAGE III
NON-SMALL CELL LUNG CANCER STAGE III Effective Date: April, 2012 The recommendations contained in this guideline are a consensus of the Alberta Provincial Thoracic Tumour Team synthesis of currently accepted
More informationUpdate on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 3: 2:45 PM - 3:30 PM Washington, DC March 28, 2009 Small Cell Lung Cancer: Best Practices & Recent Advances Speaker: Bruce E. Johnson, MD Professor of Medicine,
More informationChemotherapy in Advanced Non-Small Cell Lung Cancer: Optimal Treatment Approach for Elderly and Patients With Poor Performance Status
Chemotherapy in Advanced Non-Small Cell Lung Cancer: Optimal Treatment Approach for Elderly and Patients With Poor Performance Status Tracey L. Evans, MD Abstract In spite of advances in molecular profiling
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationTHE RESULTS OF A large meta-analysis of 52 randomized
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy By Frances A. Shepherd, Janet Dancey,
More informationHow To Know If You Have Small Cell Lung Cancer
Lung cancer Lung cancer TABLE 85 1. MALIGNANT PULMONARY NEOPLASMS INCIDENCE (%) Common 99 Non small cell lung cancer ~75 Adenocarcinoma ~35 Squamous cell carcinoma ~30 Large cell carcinoma ~10 Small cell
More informationMOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationCancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More information